This inventor holds 2 USPTO granted patents. Top assignee: Wakamoto Pharmaceutical Co., Ltd.. Active years: 1991-1993.
Location History:
- Hatano, JP (1991)
- Kanagawa, JP (1993)
Company Filing History:
Years Active: 1991-1993
Title: Takeo Ohmura: Innovator in Aldose Reductase Inhibitors
Introduction
Takeo Ohmura is a notable inventor based in Hatano, Japan. He has made significant contributions to the field of medicinal chemistry, particularly in the development of aldose reductase inhibitors. With a total of 2 patents to his name, Ohmura's work has the potential to impact the treatment of diabetic complications.
Latest Patents
Ohmura's latest patents include innovative compounds that serve as aldose reductase inhibitors. One of his notable inventions is a tetrazoleacetic acid derivative, which is represented by a specific general formula. This compound is designed to inhibit aldose reductase, which plays a crucial role in the development of diabetic complications. Another significant patent involves tetrazole derivatives that exhibit excellent aldose reductase inhibitory activity while maintaining low toxicity. These compounds are particularly useful as preventive agents and remedies for various diabetic complications, including neuropathy, retinopathy, nephropathy, cataracts, and keratopathy.
Career Highlights
Throughout his career, Takeo Ohmura has been associated with Wakamoto Pharmaceutical Co., Ltd. His work at this company has allowed him to focus on the development of pharmaceutical solutions that address critical health issues related to diabetes. His innovative approach and dedication to research have positioned him as a key figure in his field.
Collaborations
Ohmura has collaborated with esteemed colleagues such as Kiyoshi Akiba and Mitsuzi Agata. These partnerships have fostered a collaborative environment that enhances the research and development of new therapeutic agents.
Conclusion
Takeo Ohmura's contributions to the field of aldose reductase inhibitors highlight his innovative spirit and commitment to improving healthcare outcomes. His patents represent significant advancements in the treatment of diabetic complications, showcasing the importance of continued research in this area.